Abstract
Summary
Cystic fibrosis is a genetic disease that causes continuous lung infections and breathing problem over time. It is a progressive disease. The presence of imperfect gene causes a thick, sticky buildup of mucus in the lungs, intestine liver, pancreas, and other organs. The mucus in the lungs clogs airways and traps bacteria leading to infections that causes savior lung damage, and respiratory failure. The mucus prevents in the pancreas discharge the digestive enzymes that allow the body to break down food and absorb vital nutrients. This disease is caused by mutation in gene, cystic fibrosis trans membrane conductance regulator (CFTR) is a membrane protein in vertebrates, a protein required for regulating sweat, mucus and body secretions.
LPI (LP Information)' newest research report, the “Cystic Fibrosis (CF) Therapeutics Industry Forecast” looks at past sales and reviews total world Cystic Fibrosis (CF) Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Cystic Fibrosis (CF) Therapeutics sales for 2023 through 2029. With Cystic Fibrosis (CF) Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cystic Fibrosis (CF) Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Cystic Fibrosis (CF) Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cystic Fibrosis (CF) Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cystic Fibrosis (CF) Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cystic Fibrosis (CF) Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cystic Fibrosis (CF) Therapeutics.
The global Cystic Fibrosis (CF) Therapeutics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Cystic Fibrosis (CF) Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Cystic Fibrosis (CF) Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Cystic Fibrosis (CF) Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Cystic Fibrosis (CF) Therapeutics players cover Vertex Pharmaceuticalsorporated, Gilead, AbbVie,, Novartis AG, F. Hoffmann-La Roche Ltd, Alaxia, Merck & Co., AIT (Advanced Inhalation Therapies) and ALLERGAN, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Cystic Fibrosis (CF) Therapeutics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Pancreatic enzyme supplements
Mucolytics
Bronchodilators
CFTR modulators
Segmentation by application
Oral drugs
Inhaled drugs
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Vertex Pharmaceuticalsorporated
Gilead
AbbVie,
Novartis AG
F. Hoffmann-La Roche Ltd
Alaxia
Merck & Co.
AIT (Advanced Inhalation Therapies)
ALLERGAN
AstraZeneca
Teva Pharmaceutical Industries Ltd
Alcresta
LPI (LP Information)' newest research report, the “Cystic Fibrosis (CF) Therapeutics Industry Forecast” looks at past sales and reviews total world Cystic Fibrosis (CF) Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Cystic Fibrosis (CF) Therapeutics sales for 2023 through 2029. With Cystic Fibrosis (CF) Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cystic Fibrosis (CF) Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Cystic Fibrosis (CF) Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cystic Fibrosis (CF) Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cystic Fibrosis (CF) Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cystic Fibrosis (CF) Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cystic Fibrosis (CF) Therapeutics.
The global Cystic Fibrosis (CF) Therapeutics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Cystic Fibrosis (CF) Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Cystic Fibrosis (CF) Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Cystic Fibrosis (CF) Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Cystic Fibrosis (CF) Therapeutics players cover Vertex Pharmaceuticalsorporated, Gilead, AbbVie,, Novartis AG, F. Hoffmann-La Roche Ltd, Alaxia, Merck & Co., AIT (Advanced Inhalation Therapies) and ALLERGAN, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Cystic Fibrosis (CF) Therapeutics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Pancreatic enzyme supplements
Mucolytics
Bronchodilators
CFTR modulators
Segmentation by application
Oral drugs
Inhaled drugs
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Vertex Pharmaceuticalsorporated
Gilead
AbbVie,
Novartis AG
F. Hoffmann-La Roche Ltd
Alaxia
Merck & Co.
AIT (Advanced Inhalation Therapies)
ALLERGAN
AstraZeneca
Teva Pharmaceutical Industries Ltd
Alcresta
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cystic Fibrosis (CF) Therapeutics Market Size 2018-2029
2.1.2 Cystic Fibrosis (CF) Therapeutics Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Cystic Fibrosis (CF) Therapeutics Segment by Type
2.2.1 Pancreatic enzyme supplements
2.2.2 Mucolytics
2.2.3 Bronchodilators
2.2.4 CFTR modulators
2.3 Cystic Fibrosis (CF) Therapeutics Market Size by Type
2.3.1 Cystic Fibrosis (CF) Therapeutics Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Cystic Fibrosis (CF) Therapeutics Market Size Market Share by Type (2018-2023)
2.4 Cystic Fibrosis (CF) Therapeutics Segment by Application
2.4.1 Oral drugs
2.4.2 Inhaled drugs
2.5 Cystic Fibrosis (CF) Therapeutics Market Size by Application
2.5.1 Cystic Fibrosis (CF) Therapeutics Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Cystic Fibrosis (CF) Therapeutics Market Size Market Share by Application (2018-2023)
3 Cystic Fibrosis (CF) Therapeutics Market Size by Player
3.1 Cystic Fibrosis (CF) Therapeutics Market Size Market Share by Players
3.1.1 Global Cystic Fibrosis (CF) Therapeutics Revenue by Players (2018-2023)
3.1.2 Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Cystic Fibrosis (CF) Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Cystic Fibrosis (CF) Therapeutics by Regions
4.1 Cystic Fibrosis (CF) Therapeutics Market Size by Regions (2018-2023)
4.2 Americas Cystic Fibrosis (CF) Therapeutics Market Size Growth (2018-2023)
4.3 APAC Cystic Fibrosis (CF) Therapeutics Market Size Growth (2018-2023)
4.4 Europe Cystic Fibrosis (CF) Therapeutics Market Size Growth (2018-2023)
4.5 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size Growth (2018-2023)
5 Americas
5.1 Americas Cystic Fibrosis (CF) Therapeutics Market Size by Country (2018-2023)
5.2 Americas Cystic Fibrosis (CF) Therapeutics Market Size by Type (2018-2023)
5.3 Americas Cystic Fibrosis (CF) Therapeutics Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cystic Fibrosis (CF) Therapeutics Market Size by Region (2018-2023)
6.2 APAC Cystic Fibrosis (CF) Therapeutics Market Size by Type (2018-2023)
6.3 APAC Cystic Fibrosis (CF) Therapeutics Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Cystic Fibrosis (CF) Therapeutics by Country (2018-2023)
7.2 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Type (2018-2023)
7.3 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cystic Fibrosis (CF) Therapeutics by Region (2018-2023)
8.2 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Type (2018-2023)
8.3 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Cystic Fibrosis (CF) Therapeutics Market Forecast
10.1 Global Cystic Fibrosis (CF) Therapeutics Forecast by Regions (2024-2029)
10.1.1 Global Cystic Fibrosis (CF) Therapeutics Forecast by Regions (2024-2029)
10.1.2 Americas Cystic Fibrosis (CF) Therapeutics Forecast
10.1.3 APAC Cystic Fibrosis (CF) Therapeutics Forecast
10.1.4 Europe Cystic Fibrosis (CF) Therapeutics Forecast
10.1.5 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Forecast
10.2 Americas Cystic Fibrosis (CF) Therapeutics Forecast by Country (2024-2029)
10.2.1 United States Cystic Fibrosis (CF) Therapeutics Market Forecast
10.2.2 Canada Cystic Fibrosis (CF) Therapeutics Market Forecast
10.2.3 Mexico Cystic Fibrosis (CF) Therapeutics Market Forecast
10.2.4 Brazil Cystic Fibrosis (CF) Therapeutics Market Forecast
10.3 APAC Cystic Fibrosis (CF) Therapeutics Forecast by Region (2024-2029)
10.3.1 China Cystic Fibrosis (CF) Therapeutics Market Forecast
10.3.2 Japan Cystic Fibrosis (CF) Therapeutics Market Forecast
10.3.3 Korea Cystic Fibrosis (CF) Therapeutics Market Forecast
10.3.4 Southeast Asia Cystic Fibrosis (CF) Therapeutics Market Forecast
10.3.5 India Cystic Fibrosis (CF) Therapeutics Market Forecast
10.3.6 Australia Cystic Fibrosis (CF) Therapeutics Market Forecast
10.4 Europe Cystic Fibrosis (CF) Therapeutics Forecast by Country (2024-2029)
10.4.1 Germany Cystic Fibrosis (CF) Therapeutics Market Forecast
10.4.2 France Cystic Fibrosis (CF) Therapeutics Market Forecast
10.4.3 UK Cystic Fibrosis (CF) Therapeutics Market Forecast
10.4.4 Italy Cystic Fibrosis (CF) Therapeutics Market Forecast
10.4.5 Russia Cystic Fibrosis (CF) Therapeutics Market Forecast
10.5 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Forecast by Region (2024-2029)
10.5.1 Egypt Cystic Fibrosis (CF) Therapeutics Market Forecast
10.5.2 South Africa Cystic Fibrosis (CF) Therapeutics Market Forecast
10.5.3 Israel Cystic Fibrosis (CF) Therapeutics Market Forecast
10.5.4 Turkey Cystic Fibrosis (CF) Therapeutics Market Forecast
10.5.5 GCC Countries Cystic Fibrosis (CF) Therapeutics Market Forecast
10.6 Global Cystic Fibrosis (CF) Therapeutics Forecast by Type (2024-2029)
10.7 Global Cystic Fibrosis (CF) Therapeutics Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Vertex Pharmaceuticalsorporated
11.1.1 Vertex Pharmaceuticalsorporated Company Information
11.1.2 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Product Offered
11.1.3 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Vertex Pharmaceuticalsorporated Main Business Overview
11.1.5 Vertex Pharmaceuticalsorporated Latest Developments
11.2 Gilead
11.2.1 Gilead Company Information
11.2.2 Gilead Cystic Fibrosis (CF) Therapeutics Product Offered
11.2.3 Gilead Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Gilead Main Business Overview
11.2.5 Gilead Latest Developments
11.3 AbbVie,
11.3.1 AbbVie, Company Information
11.3.2 AbbVie, Cystic Fibrosis (CF) Therapeutics Product Offered
11.3.3 AbbVie, Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 AbbVie, Main Business Overview
11.3.5 AbbVie, Latest Developments
11.4 Novartis AG
11.4.1 Novartis AG Company Information
11.4.2 Novartis AG Cystic Fibrosis (CF) Therapeutics Product Offered
11.4.3 Novartis AG Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Novartis AG Main Business Overview
11.4.5 Novartis AG Latest Developments
11.5 F. Hoffmann-La Roche Ltd
11.5.1 F. Hoffmann-La Roche Ltd Company Information
11.5.2 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Product Offered
11.5.3 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 F. Hoffmann-La Roche Ltd Main Business Overview
11.5.5 F. Hoffmann-La Roche Ltd Latest Developments
11.6 Alaxia
11.6.1 Alaxia Company Information
11.6.2 Alaxia Cystic Fibrosis (CF) Therapeutics Product Offered
11.6.3 Alaxia Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Alaxia Main Business Overview
11.6.5 Alaxia Latest Developments
11.7 Merck & Co.
11.7.1 Merck & Co. Company Information
11.7.2 Merck & Co. Cystic Fibrosis (CF) Therapeutics Product Offered
11.7.3 Merck & Co. Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Merck & Co. Main Business Overview
11.7.5 Merck & Co. Latest Developments
11.8 AIT (Advanced Inhalation Therapies)
11.8.1 AIT (Advanced Inhalation Therapies) Company Information
11.8.2 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Product Offered
11.8.3 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 AIT (Advanced Inhalation Therapies) Main Business Overview
11.8.5 AIT (Advanced Inhalation Therapies) Latest Developments
11.9 ALLERGAN
11.9.1 ALLERGAN Company Information
11.9.2 ALLERGAN Cystic Fibrosis (CF) Therapeutics Product Offered
11.9.3 ALLERGAN Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 ALLERGAN Main Business Overview
11.9.5 ALLERGAN Latest Developments
11.10 AstraZeneca
11.10.1 AstraZeneca Company Information
11.10.2 AstraZeneca Cystic Fibrosis (CF) Therapeutics Product Offered
11.10.3 AstraZeneca Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 AstraZeneca Main Business Overview
11.10.5 AstraZeneca Latest Developments
11.11 Teva Pharmaceutical Industries Ltd
11.11.1 Teva Pharmaceutical Industries Ltd Company Information
11.11.2 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Product Offered
11.11.3 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Teva Pharmaceutical Industries Ltd Main Business Overview
11.11.5 Teva Pharmaceutical Industries Ltd Latest Developments
11.12 Alcresta
11.12.1 Alcresta Company Information
11.12.2 Alcresta Cystic Fibrosis (CF) Therapeutics Product Offered
11.12.3 Alcresta Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Alcresta Main Business Overview
11.12.5 Alcresta Latest Developments
12 Research Findings and Conclusion